FDA wants yet more data on Takeda diabetes drug alogliptin

Article Date: 26/04/2012 10:00
FDA wants yet more data on Takeda diabetes drug alogliptin

Vacancy Search

Quick job search

Advanced Search

Latest News

Vantage Point – Risk-averse European VCs drive medtech start-ups to crowdfunding

Best known as the preserve of tech and IT companies, crowdfunding is becoming a firmer fixture in the world of medtech financing. While the well-documented shortfall in VC funding for...

Pharma spends big on M&A in Q1 as Teva pulls trigger on Mylan

The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma  data show....

EXCLUSIVE: New data backs 'pulsatile' statin dosing

EXCLUSIVE: New data backs 'pulsatile' statin dosing

GP prescribing costs hit £9.16 bn in 2014

GP prescribing costs hit £9.16 bn in 2014

Merck, Pfizer put avelumab into PhIII NSCLC trial

Merck, Pfizer put avelumab into PhIII NSCLC trial

Roche, Curadev sign $555m cancer immunotherapy deal

Roche, Curadev sign $555m cancer immunotherapy deal

Takeda in research pact with Keio, Niigata universities

Takeda in research pact with Keio, Niigata universities

EMA scientific advice on trials boosts success rate

EMA scientific advice on trials boosts success rate

Mylan dismisses Teva bid

Mylan dismisses Teva bid

AACR – Solid tumour CAR-T foray lives up to its low-key billing

For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that...
more news